Survival of skin allografts is prolonged in mice with a dominant-negative H-Ras

Transplant Immunology

Volumn 18, Issue 4, 2008, Pages 302-306

  Funeshima Fuji, Naoko ^a,c   Fujino, Masayuki ^a,b   Kimura, Hiromitsu ^a   Takahara, Shiro ^d   Nakayama, Toshinori ^e   Ezaki, Taichi ^c   Li, Xiao Kang ^a  

^a NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e CHIBA UNIVERSITY   (Japan)

Author keywords

Dominant negative; Ras; Skin graft; Transgenic mouse

Indexed keywords

ALLOANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOTIDE BINDING PROTEIN; RAS PROTEIN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FULL THICKNESS SKIN GRAFT; GRAFT REJECTION; GRAFT SURVIVAL; LYMPHOCYTE PROLIFERATION; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN ALLOGRAFT; TRANSGENIC MOUSE;

ANIMALS; GENES, DOMINANT; GENES, RAS; GRAFT REJECTION; GRAFT SURVIVAL; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; RAS PROTEINS; SKIN TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 37349100144     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2007.10.009     Document Type: Article

References (24)

1. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3 (2003) 11
2. Hancock J.F. Ras proteins: different signals from different locations. Nat Rev Mol Cell Biol 4 (2003) 373
3. Oxford G., and Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cell motility. Cancer Lett 189 (2003) 117
4. Kikuchi A., and Williams L.T. The post-translational modification of ras p21 is important for Raf-1 activation. J Biol Chem 269 (1994) 20054
5. Downward J., Graves J.D., Warne P.H., Rayter S., and Cantrell D.A. Stimulation of p21ras upon T-cell activation. Nature 346 (1990) 719
6. Woodrow M., Clipstone N.A., and Cantrell D. p21ras and calcineurin synergize to regulate the nuclear factor of activated T cells. J Exp Med 178 (1993) 1517
7. Rayter S.I., Woodrow M., Lucas S.C., Cantrell D.A., and Downward J. p21ras mediates control of IL-2 gene promoter function in T cell activation. Embo J 11 (1992) 4549
8. Lafont V., Ottones F., Liautard J., and Favero J. Evidence for a p21(ras)/Raf-1/MEK-1/ERK-2-independent pathway in stimulation of IL-2 gene transcription in human primary T lymphocytes. J Biol Chem 274 (1999) 25743
9. Swan K.A., Alberola-Ila J., Gross J.A., Appleby M.W., Forbush K.A., Thomas J.F., et al. Involvement of p21ras distinguishes positive and negative selection in thymocytes. Embo J 14 2 (1995) 276-285
10. Miyamoto M., Furui K., and Kimura H. Male skin isografts can induce unresponsiveness in female rats. Transplantation 30 (1980) 180
11. Funeshima N., Fujino M., Kitazawa Y., Hara Y., Hara Y., Hayakawa K., et al. Inhibition of allogeneic T-cell responses by dendritic cells expressing transduced indoleamine 2,3-dioxygenase. J Gene Med 7 5 (2005) 565-575
12. Cantrell D.A. GTPases and T cell activation. Immunol Rev 192 (2003) 122
13. Si M.S., Ji P., Lee M., Kwok J., Kusumoto J., Naasz E., et al. Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection. J Heart Lung Transplant 24 9 (2005) 1403-1409
14. Rapoport M.J., Lazarus A.H., Jaramillo A., Speck E., and Delovitch T.L. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21ras activation. J Exp Med 177 (1993) 1221
15. Fields P.E., Gajewski T.F., and Fitch F.W. Blocked Ras activation in anergic CD4+ T cells. Science 271 (1996) 1276
16. Yamashita M., Kimura M., Kubo M., Shimizu C., Tada T., Perlmutter R.M., et al. T cell antigen receptor-mediated activation of the Ras/mitogen-activated protein kinase pathway controls interleukin 4 receptor function and type-2 helper T cell differentiation. Proc Natl Acad Sci U S A 96 3 (1999) 1024-1029
17. Li W., Whaley C.D., Mondino A., and Mueller D.L. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science 271 (1996) 1272
18. Kang S.M., Beverly B., Tran A.C., Brorson K., Schwartz R.H., and Lenardo M.J. Transactivation by AP-1 is a molecular target of T cell clonal anergy. Science 257 (1992) 1134
19. Zha Y., Marks R., Ho A.W., Peterson A.C., Janardhan S., Brown I., et al. T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-alpha. Nat Immunol 7 11 (2006) 1166-1173 (Epub 2006 Oct 8)
20. Thornton A.M., and Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 188 (1998) 287
21. Li L., Godfrey W.R., Porter S.B., et al. CD4 + CD25 + regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 106 (2005) 3068
22. Hickman S.P., Yang J., Thomas R.M., Wells A.D., and Turka L.A. Defective activation of protein kinase C and Ras-ERK pathways limits IL-2 production and proliferation by CD4 + CD25 + regulatory T cells. J Immunol 177 (2006) 2186
23. Berg N.N., Puente L.G., Dawicki W., and Ostergaard H.L. Sustained TCR signaling is required for mitogen-activated protein kinase activation and degranulation by cytotoxic T lymphocytes. J Immunol 161 (1998) 2919
24. Puente L.G., He J.S., and Ostergaard H.L. A novel PKC regulates ERK activation and degranulation of cytotoxic T lymphocytes: plasticity in PKC regulation of ERK. Eur J Immunol 36 (2006) 1009